View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

  • Notice Summary
    United Kingdom-Runcorn: National Pharmaceuticals Transition
    210460-2019
    The NHS Commissioning Board (operating under the name of NHS England)
    07 May 2019
    07 June 2019
    Contract Notice - Open Procedure
  • Notice Abstract

    Invitation to offer for NHS National Pharmaceuticals Transition 2019_1Offer reference number: CM/PHG/17/5547Period of Framework Agreement: The total maximum duration of the Framework Agreement to be no more than 34 monthspotential periods of call-offs under the Framework Agreement:— LSNE: 1.10.2019 to 30.4.2020 (7 months),— CESW: 1.10.2019 to 30.9.2020 (12 months),— NWLN: 1.10.2019 to 28.2.2021 (17 months).Products on the framework include (but are not limited to):— aprepitant,— arsenic,— atazanavir,— atomoxetine,— atovaquone,— bortezomib,— carglumic acid,— clofarabine,— darunavir,— dasatinib,— dexmedetomidine,— everolimus,— fondaparinux,— ganciclovir,— gefitinib,— iloprost,— iron sucrose,— lanthanum,— melphalan,— metaraminol,— miglustat,— nabilone,— olopatadine,— prasugrel,— ritonavir,— solifenacin,— trientine.Details of presentation sizes and volumes are within the tender document set.

  • Notice Details

    Contract notice

    Directive 2014/24/EU - Public Sector Directive

    Directive 2014/24/EU

    Section I: Contracting Change entity

    I.1) Name and addresses

    The NHS Commissioning Board (operating under the name of NHS England)

    2nd Floor, Rutland House

    Runcorn

    WA7 2ES

    UK

    E-mail: gemma.tomlinson1@nhs.net

    NUTS: UK

    Internet address(es)

    Main address: https://nhsengland.bravosolution.co.uk

    I.2) Joint procurement

    The contract is awarded by a central purchasing body

    I.3) Communication

    The procurement documents are available for unrestricted and full direct access, free of charge at:

    https://nhsengland.bravosolution.co.uk


    Additional information can be obtained from the abovementioned address


    Tenders or requests to participate must be sent electronically to:

    https://nhsengland.bravosolution.co.uk


    Tenders or requests to participate must be sent to the abovementioned address


    I.4) Type of the contracting authority

    Ministry or any other national or federal authority, including their regional or local subdivisions

    I.5) Main activity

    Health

    Section II: Object

    II.1) Scope of the procurement

    II.1.1) Title

    NHS National Pharmaceuticals Transition 2019_1

    Reference number: CM/PHG/17/5547

    II.1.2) Main CPV code

    33600000

     

    II.1.3) Type of contract

    Supplies

    II.1.4) Short description

    Invitation to offer for NHS National Pharmaceuticals Transition 2019_1

    Offer reference number: CM/PHG/17/5547

    Period of Framework Agreement: The total maximum duration of the Framework Agreement to be no more than 34 months

    potential periods of call-offs under the Framework Agreement:

    — LSNE: 1.10.2019 to 30.4.2020 (7 months),

    — CESW: 1.10.2019 to 30.9.2020 (12 months),

    — NWLN: 1.10.2019 to 28.2.2021 (17 months).

    Products on the framework include (but are not limited to):

    — aprepitant,

    — arsenic,

    — atazanavir,

    — atomoxetine,

    — atovaquone,

    — bortezomib,

    — carglumic acid,

    — clofarabine,

    — darunavir,

    — dasatinib,

    — dexmedetomidine,

    — everolimus,

    — fondaparinux,

    — ganciclovir,

    — gefitinib,

    — iloprost,

    — iron sucrose,

    — lanthanum,

    — melphalan,

    — metaraminol,

    — miglustat,

    — nabilone,

    — olopatadine,

    — prasugrel,

    — ritonavir,

    — solifenacin,

    — trientine.

    Details of presentation sizes and volumes are within the tender document set.

    II.1.5) Estimated total value

    Value excluding VAT: 234 870 322.85 GBP

    II.1.6) Information about lots

    This contract is divided into lots: Yes

    Tenders may be submitted for all lots

    II.2) Description

    Lot No: 01

    II.2.1) Title

    LSNE: 1.10.2019 to 30.4.2020 (7 Months)

    II.2.2) Additional CPV code(s)

    33600000

    33690000

    II.2.3) Place of performance

    NUTS code:

    UK


    Main site or place of performance:

    Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points.

    II.2.4) Description of the procurement

    NHS National Pharmaceuticals Transition 2019_1

    Offer reference number: CM/PHG/17/5547

    Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 34 months potential periods of call-offs under the Framework Agreement:

    — LSNE: 1.10.2019 to 30.4.2020 (7 months),

    — CESW: 1.10.2019 to 30.9.2020 (12 months),

    — NWLN: 1.10.2019 to 28.2.2021 (17 months).

    II.2.5) Award criteria

    Price is not the only award criterion and all criteria are stated only in the procurement documents

    II.2.6) Estimated value

    Value excluding VAT: 40 483 765.16 GBP

    II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

    Start: 01/10/2019

    End: 30/04/2020

    This contract is subject to renewal: No

    II.2.9) Information about the limits on the number of candidates to be invited

    II.2.10) Information about variants

    Variants will be accepted: No

    II.2.11) Information about options

    Options: Yes

    Description of options:

    This framework has the option for the LSNE region to extend for up to a maximum of 7 months.

    II.2.13) Information about European Union funds

    The procurement is related to a project and/or programme financed by European Union funds: No

    Lot No: 02

    II.2.1) Title

    CESW: 1.10.2019 to 30.9.2020 (12 Months)

    II.2.2) Additional CPV code(s)

    33600000

    33690000

    II.2.3) Place of performance

    NUTS code:

    UK


    Main site or place of performance:

    Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

    II.2.4) Description of the procurement

    NHS National Pharmaceuticals Transition 2019_1

    Offer reference number: CM/PHG/17/5547

    Period of Framework Agreement: The total maximum duration of the Framework Agreement to be no more than 34 months potential periods of call-offs under the Framework Agreement:

    — LSNE: 1.10.2019 to 30.4.2020 (7 months),

    — CESW: 1.10.2019 to 30.9.2020 (12 months),

    — NWLN: 1.10.2019 to 28.2.2021 (17 months).

    II.2.5) Award criteria

    Price is not the only award criterion and all criteria are stated only in the procurement documents

    II.2.6) Estimated value

    Value excluding VAT: 64 975 040.40 GBP

    II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

    Start: 01/10/2019

    End: 30/09/2020

    This contract is subject to renewal: No

    II.2.9) Information about the limits on the number of candidates to be invited

    II.2.10) Information about variants

    Variants will be accepted: No

    II.2.11) Information about options

    Options: Yes

    Description of options:

    This framework has the option for the CESW region to extend for up to a maximum of 12 months.

    II.2.13) Information about European Union funds

    The procurement is related to a project and/or programme financed by European Union funds: No

    Lot No: 03

    II.2.1) Title

    NWLN: 1.10.2019 to 28.2.2021 (17 Months)

    II.2.2) Additional CPV code(s)

    33600000

    33690000

    II.2.3) Place of performance

    NUTS code:

    UK


    Main site or place of performance:

    Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

    II.2.4) Description of the procurement

    NHS National Pharmaceuticals Transition 2019_1

    Offer reference number: CM/PHG/17/5547

    Period of Framework Agreement: The total maximum duration of the Framework Agreement to be no more than 34 months potential periods of call-offs under the Framework Agreement:

    LSNE: 1.10.2019 to 30.4.2020 (7 months),

    CESW: 1.10.2019 to 30.9.2020 (12 months),

    NWLN: 1.10.2019 to 28.2.2021 (17 months).

    II.2.5) Award criteria

    Price is not the only award criterion and all criteria are stated only in the procurement documents

    II.2.6) Estimated value

    Value excluding VAT: 129 411 517.29 GBP

    II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

    Start: 01/10/2019

    End: 28/02/2021

    This contract is subject to renewal: No

    II.2.9) Information about the limits on the number of candidates to be invited

    II.2.10) Information about variants

    Variants will be accepted: No

    II.2.11) Information about options

    Options: Yes

    Description of options:

    This framework has the option for the NWLN region to extend for up to a maximum of 17 months.

    II.2.13) Information about European Union funds

    The procurement is related to a project and/or programme financed by European Union funds: No

    Section IV: Procedure

    IV.1) Description

    IV.1.1) Type of procedure

    Open procedure

    IV.1.3) Information about a framework agreement or a dynamic purchasing system

    The procurement involves the establishment of a framework agreement with several operators.

    IV.1.8) Information about Government Procurement Agreement (GPA)

    The procurement is covered by the Government Procurement Agreement: Yes

    IV.2) Administrative information

    IV.2.2) Time limit for receipt of tenders or requests to participate

    Date: 07/06/2019

    Local time: 13:00

    IV.2.4) Languages in which tenders or requests to participate may be submitted

    EN

    IV.2.7) Conditions for opening of tenders

    Date: 07/06/2019

    Local time: 13:00

    Place:

    Runcorn

    Information about authorised persons and opening procedure:

    Commercial medicines unit employee.

    Section VI: Complementary information

    VI.1) Information about recurrence

    This is a recurrent procurement: No

    VI.2) Information about electronic workflows

    Electronic ordering will be used

    Electronic invoicing will be accepted

    Electronic payment will be used

    VI.3) Additional information

    Responding to this notice:

    Any supplier may be disqualified who does not respond to the following in the requisite manner:

    1) Submission of expression of interest and procurement specific information this procurement exercise will be conducted on the eTendering portal at https://nhsengland.bravosolution.co.uk.

    Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested), through the eTendering portal as follows:

    1.1) If not already registered, candidates should register on the eTendering portal at

    https://nhsengland.bravosolution.co.uk/web/login.html and click the link to register:

    — accept the terms and conditions and click continue,

    — enter your correct business and user details,

    — note the username you chose and click “Save” when complete,

    — you will shortly receive an email with your unique password (please keep this secure).

    1.2) Once registered, candidates must express interest as follows:

    (a) login to the eTendering portal;

    (b) select “Response to ITT”;

    (c) select “ITTs Open To All Suppliers”;

    (d) access listing related to this procurement, NHS National Pharmaceuticals Transition 2019_1; and

    view details;

    (e) click on “Express interest” button at the top of the page;

    (f) Once you have expressed interest, the ITT will move to “My ITTs”, where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the “Publish” button.

    1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 800 368 4850 or help@bravosolution.co.uk.

    2) General supplier information.

    To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:

    2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.uk and select “Register” at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on the system;

    2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B;

    2.3) For further help or information concerning sid4gov, please contact the sid4gov Helpdesk at:

    support@nqc.com or telephone +44 (0) 845 299 2994.

    Other Contracting Authorities:

    The Framework Agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

    VI.4) Procedures for review

    VI.4.1) Review body

    The Royal Courts of Justice

    London or any other district registry of the High Court

    UK

    VI.5) Date of dispatch of this notice

    03/05/2019